Science & Enterprise subscription

Follow us on Twitter

  • Spark Therapeutics, a developer of gene therapies, is gaining access to a technology that programs DNA sequences li… https://t.co/WGboSsrf7U
    about 16 hours ago
  • New post on Science and Enterprise: Gene Therapy Company Exploring DNA Circuit Technology https://t.co/2YUM4DVZRK #Science #Business
    about 16 hours ago
  • A study with lab mice shows an experimental vaccine with engineered bacteria produces antibodies and protects again… https://t.co/3JtSqD1Sa2
    about 20 hours ago
  • New post on Science and Enterprise: Vaccine Stops Lyme Bacteria in Preclinical Test https://t.co/7H0Lc90nRe #Science #Business
    about 20 hours ago
  • Stop the panic porn ... Coronavirus Variants Don’t Have to Be Scary. Still, Mask Up. https://t.co/d6aDu2Ucj6
    about 23 hours ago

Please share Science & Enterprise

Molecular Diagnostics Company Acquired in $1.8B Deal

Investment graphic

GenMark Diagnostics, a developer of diagnostics systems using genomic analysis, was acquired by drug maker Roche in a deal valued at $1.8 billion. . . . → Read More: Molecular Diagnostics Company Acquired in $1.8B Deal

Gene-Editing Biotech Acquires DNA Bar Code Company

DNA chip graphic

A developer of therapies using highly precise gene editing is acquiring a company delivering gene therapies identified with DNA bar codes. . . . → Read More: Gene-Editing Biotech Acquires DNA Bar Code Company

Cannabidiol Drug Maker Acquired in $7.2B Deal

Cannabis plant

A developer of treatments for rare neurological diseases derived from cannabis is being acquired by Jazz Pharmaceuticals in a $7.2 billion deal. . . . → Read More: Cannabidiol Drug Maker Acquired in $7.2B Deal

2020 Venture Funds Mixed, Biotech Keeps Sizzling

2020 venture transactions

Total venture investments in dollars jumped to a new high in the U.S., while biotechnology remained the single hottest sector in 2020. . . . → Read More: 2020 Venture Funds Mixed, Biotech Keeps Sizzling

Neuroscience Biotech Acquired in $770M Deal

Brain activity graphic

A three year-old biotechnology company developing treatments for psychiatric and movement disorders is being acquired by global drug maker Novartis. . . . → Read More: Neuroscience Biotech Acquired in $770M Deal

Oral Drug Delivery Company Acquired in $1.8B Deal

Investor screen

Emisphere Technologies, developers of a process that makes biologic drugs available as oral medicines is being acquired by drug maker Novo Nordisk. . . . → Read More: Oral Drug Delivery Company Acquired in $1.8B Deal

Venture Rounds, IPOs, Mergers Vanish in Election Week

White House

Nationwide jitters in the U.S. appear to be affecting venture capital activities in the week of the presidential and congressional elections. . . . → Read More: Venture Rounds, IPOs, Mergers Vanish in Election Week

Bayer Gains Gene Therapy Biotech in $4B Deal

AskBio Bioreactor

Global drug maker Bayer AG is acquiring the company Asklepios BioPharmaceutical, developer of gene therapies to treat inherited disorders. . . . → Read More: Bayer Gains Gene Therapy Biotech in $4B Deal

Lilly Gains Neuro Disease Biotech in $1.36B Deal

Nerve cells illustration

Drug maker Eli Lilly and Co. is acquiring Disarm Therapeutics, a biotechnology company developing treatments for neurodegenerative disorders. . . . → Read More: Lilly Gains Neuro Disease Biotech in $1.36B Deal

Heart Disease Biotech Acquired in $13.1B Deal

Wall Street sign

A company developing precision medicine drugs to treat inherited heart disorders was acquired by drug maker Bristol Myers Squibb, or BMS, for $13.1 billion. . . . → Read More: Heart Disease Biotech Acquired in $13.1B Deal